Easing the Transition to the First Injectable for People with Type 2 Diabetes – ADEA Certificate of Endorsement

CDEs play an instrumental role in helping persons with T2D transition to their first injectable therapy at the appropriate time. This involves effectively communicating physiological benefits of GLP-1RA treatment, as well as assisting in effectively navigating patient concerns, such as injection technique. Based on the individual needs of the patient, strategies to improve patient acceptability to injectable therapy and ongoing management can then be developed, thereby addressing any reasons for patient inertia that may be present.